STOCK TITAN

Hookipa Pharma Inc - HOOK STOCK NEWS

Welcome to our dedicated news page for Hookipa Pharma (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hookipa Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hookipa Pharma's position in the market.

Rhea-AI Summary
HOOKIPA Pharma Inc. announced strategic priorities to focus on advancing clinical programs for HPV16+ head and neck cancers and Gilead-partnered infectious disease programs. The company will prioritize the clinical development of a randomized trial for HB-200 in HPV16+ head and neck squamous cell carcinoma, implement cost-saving initiatives, and reduce its workforce by 30 percent. HOOKIPA will also regain global development rights to HB-700 program for KRAS-mutated cancers from Roche and maintain a strong cash position of $117.5 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.13%
Tags
partnership
-
Rhea-AI Summary
HOOKIPA Pharma Inc. appoints Mark Winderlich, PhD, as Chief Development Officer, effective April 1, 2024. Dr. Winderlich brings extensive experience in leading drug development processes and will focus on advancing the HB-200 program to improve the standard of care for people with advanced HPV16+ head and neck cancer. He joins HOOKIPA from Evotec SE, where he led the partnership with Bristol Myers Squibb in oncology and played key roles in the development of multiple drug candidates. Dr. Winderlich's appointment reflects HOOKIPA's commitment to advancing novel arenaviral therapies for cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.15%
Tags
management clinical trial
-
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced that Gilead Sciences has purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of $1.4167 per share. Following the transaction, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock. The equity investment aims to advance the Gilead-partnered HIV therapeutic program through Phase 1, with the trial expected to commence in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.74%
Tags
none
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has received FDA clearance for its Investigational New Drug (IND) application for HB-500, a novel arenaviral therapeutic vaccine for the treatment of HIV. The Phase 1 trial will commence in the first half of 2024, following the publication of peer-reviewed preclinical data in Nature Partner Journals (NPJ) Vaccines. The vaccine has shown safety, immunogenicity, and efficacy in preclinical testing, and Gilead Sciences, Inc. has the exclusive right to assume further development of the program after HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
clinical trial
-
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported positive preliminary Phase 2 data for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer. The data reinforce strong objective response rate and disease control rate reported in Q2 2023. The company also published peer-reviewed preclinical data for HB-400 program in The Journal of Infectious Disease. Recruitment is ongoing for two Phase 1 clinical trials for advanced prostate cancer and chronic hepatitis B. IND-enabling activities are in progress to advance two additional therapeutic candidates into the clinic in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12%
Tags
earnings
-
Rhea-AI Summary
HOOKIPA Pharma Inc. announced updated Phase 1 clinical data on HB-200 as a monotherapy in patients with recurrent/metastatic HPV16+ head and neck cancer. The data show that HB-200 induced robust tumor-specific T cell responses, with a 44 percent disease control rate in a difficult-to-treat patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
none
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its third quarter 2023 financial results and business highlights on November 9, 2023. No conference call will be conducted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
conferences earnings
-
Rhea-AI Summary
HOOKIPA Pharma presents updated data from Phase 2 trial of HB-200 in combination with pembrolizumab for head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
HOOKIPA Pharma announces publication of preclinical data on HB-400, a potential therapeutic vaccine for chronic hepatitis B
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
clinical trial
Rhea-AI Summary
HOOKIPA Pharma's Chief Medical Officer, Katia Schlienger, is stepping down to pursue new opportunities, effective September 30. Malte Peters, a current member of the Board of Directors, will lead clinical activities ad interim. Peters has extensive experience in bringing new therapies to patients. HOOKIPA remains focused on executing clinical priorities and progressing their programs with Roche and Gilead.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
management
Hookipa Pharma Inc

Nasdaq:HOOK

HOOK Rankings

HOOK Stock Data

67.71M
49.47M
23.19%
46.58%
0.45%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
New York

About HOOK

hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a